Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于公司及子公司使用闲置自有资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase wealth management products. It details amounts, dates, risk disclosures, and risk control measures related to these financial activities. The document is relatively short (3655 characters) and focuses on informing shareholders and the public about the company's cash management and investment activities rather than presenting comprehensive financial statements or results. It does not contain full financial reports, audit opinions, or detailed management analysis. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to updates on the company's use of funds and financial management activities involving capital deployment into financial products.
2024-08-26 Chinese
金陵药业股份有限公司关于变更注册资本暨修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding changes to the registered capital and amendments to the company's articles of association. It details the reduction in registered capital due to the repurchase and cancellation of restricted shares and the corresponding amendments to the company's charter. The document is relatively short (924 characters) and serves as a formal announcement of these corporate actions rather than a full report or detailed financial statement. It does not contain financial results, audit information, or detailed management discussion. The content fits best under the category of Share Issue/Capital Change (SHA), which covers announcements about changes in share capital and related corporate governance documents.
2024-08-26 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "金陵药业股份有限公司2024 年半年度报告全文" which translates to "Jinling Pharmaceutical Co., Ltd. 2024 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2024 to June 30, 2024. The content includes detailed financial data, management discussion and analysis, business overview, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and mentions that some proposals will be submitted to the shareholders' meeting. It also references the approval of the company's 2024 semi-annual report and related reports but does not contain the actual financial data or the full report itself. The document is relatively short (1947 characters) and serves as an official announcement of meeting resolutions and supervisory opinions rather than a full financial report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal disclosure of supervisory board meeting resolutions and related announcements that do not fit into other specific categories like Interim Report or Management Reports.
2024-08-26 Chinese
金陵药业股份有限公司关于调整公司高级管理人员职务及聘任公司总裁助理的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding adjustments in senior management positions and the appointment of an assistant to the company president. It includes details about the individuals' resumes and shareholdings. There is no financial data, no mention of a report or meeting results, and it focuses solely on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2024-08-26 Chinese
金陵药业股份有限公司监事会关于第九届监事会第十二次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's audit opinion on various company matters, including the review of the 2024 semi-annual report, stock incentive plan adjustments, and use of raised funds. It contains detailed opinions on compliance with laws and regulations, and specifically mentions the 2024 semi-annual report and related financial matters. The document is not the report itself but an audit opinion related to the interim report and other corporate governance issues. Given the focus on audit opinions and compliance review without presenting full financial statements, this fits the category of an Audit Report / Information (AR). The document length is short and it is not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. H1 2024
2024-08-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.